ScholarIQanswers from OpenAlex & ORCID
Chong‐Jen Yu
ResearcherPublications, citations & collaboration network
Chong‐Jen Yu is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Chong‐Jen Yu have?
ScholarIQindexed works
Chong‐Jen Yu has 959 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Chong‐Jen Yu have?
ScholarIQcitation count
Chong‐Jen Yu has 37,776 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Chong‐Jen Yu?
ScholarIQh-index
Chong‐Jen Yu has an h-index of 90 in OpenAlex.
What is the i10-index of Chong‐Jen Yu?
ScholarIQi10-index
Chong‐Jen Yu has an i10-index of 506 in OpenAlex.
What is the ORCID of Chong‐Jen Yu?
ScholarIQorcid
The ORCID for Chong‐Jen Yu is on the source record.
What is the OpenAlex record for Chong‐Jen Yu?
ScholarIQopenalex
The OpenAlex for Chong‐Jen Yu is on the source record.
What are the most-cited papers on Chong‐Jen Yu?
ScholarIQmost cited works
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
Yi‐Long Wu, Masahiro Tsuboi, Jie He, Thomas John, Christian Grohé, Margarita Majem, Jonathan W. Goldman, К. К. Лактионов, Sang‐We Kim, Terufumi Kato, Huu-Vinh Vu, Shun Lü, Kye Young Lee, Charuwan Akewanlop, Chong‐Jen Yu, Filippo de Marinis, Laura Bonanno, Manuel Dómine, Frances A. Shepherd, Lingmin Zeng, Rachel Hodge, Ajlan Atasoy, Yuri Rukazenkov, Roy S. Herbst
<i>MET</i> amplification occurs with or without <i>T790M</i> mutations in <i>EGFR</i> mutant lung tumors with acquired resistance to gefitinib or erlotinib
James Bean, Cameron Brennan, Jin‐Yuan Shih, Gregory J. Riely, Agnès Viale, Lu Wang, Dhananjay Chitale, Noriko Motoi, János Szőke, Stephen Broderick, Marissa N. Balak, W.C. Chang, Chong‐Jen Yu, Adi F. Gazdar, Harvey I. Pass, Valerie W. Rusch, William L. Gerald, Shiu‐Feng Huang, Pan‐Chyr Yang, Vincent A. Miller, Marc Ladanyi, Chih-Hsin Yang, William Pao
First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
Jean‐Charles Soria, Daniel S.W. Tan, Rita Chiari, Yi‐Long Wu, Luis Paz‐Ares, Juergen Wolf, Sarayut Lucien Geater, С. В. Орлов, Diego Cortinovis, Chong‐Jen Yu, Maximillian Hochmair, Alexis B. Cortot, Chun‐Ming Tsai, Denis Moro‐Sibilot, Rosario García Campelo, Tracey McCulloch, Paramita Sen, Margaret Dugan, Serafino Pantano, Fabrice Branle, Cristian Massacesi, Gilberto de Castro
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
James Chih‐Hsin Yang, Lecia V. Sequist, Sarayut Lucien Geater, Chun-Ming Tsai, Tony Mok, Martin Schüler, Nobuyuki Yamamoto, Chong‐Jen Yu, Sai‐Hong Ignatius Ou, Caicun Zhou, Daniel Massey, Victoria Zazulina, Yi‐Long Wu
Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia
Guangchang Pei, Zhiguo Zhang, Jing Peng, Liu Liu, Chunxiu Zhang, Chong‐Jen Yu, Zufu Ma, Yi Huang, Wei Liu, Ying Yao, Rui Zeng, Gang Xu